Role of advanced glycation end products and insulin resistance in diabetic nephropathy

2020 ◽  
pp. 1-13
Author(s):  
Kirti Parwani ◽  
Palash Mandal
Keyword(s):  
Insulin Resistance ◽  
Diabetic Nephropathy ◽  
Advanced Glycation End Products ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products

scholarly journals The role of advanced glycation end products in patogenesis of diabetic nephropathy

2022 ◽  
Vol 24 (5) ◽  
pp. 461-469
Author(s):  
A. O. Gavrilova ◽  
A. S. Severina ◽  
M. S. Shamhalova ◽  
M. V. Shestakova
Keyword(s):  
Diabetic Nephropathy ◽  
Advanced Glycation End Products ◽  
Therapeutic Approaches ◽  
Advanced Glycation ◽  
New Therapeutic Approaches ◽  
Slow Progression ◽  
Glycation End Products ◽  
The World ◽  
End Products

Diabetes mellitus (DM) and chronic kidney disease are the diseases that have exceeded epidemic thresholds in terms of prevalence all over the world. That made it possible to classify them as non-communicable epidemics of the XXI century. Diabetic nephropathy (DN) is implicated with high levels of disablement and mortality. Advanced glycation end products (AGE) play a key role in the progression of DN. Increased formation of AGE occurs due to hyperglycemia under the conditions of diabetes. Moreover, there are additional factors in DN that increase the elaboration of AGE, such as high levels of oxidative stress and decreased renal clearance which slows down the AGE excretion. Both immediate effects of AGE and interaction of AGE with its cell-bound receptor (RAGE) result in a сascade of events that lead to further progression of DN. Thus, the research of the new therapeutic approaches targeted on the AGE-RAGE system is of great interest to slow progression of DN and improve the prognosis.

Role of advanced glycation end products in adynamic bone disease in patients with diabetic nephropathy

2001 ◽  
Vol 38 (4) ◽  
pp. S161-S164 ◽  
Author(s):  
Takehisa Yamamoto ◽  
Keiichi Ozono ◽  
Akimitsu Miyauchi ◽  
Soji Kasayama ◽  
Yasuyuki Kojima ◽  
...  
Keyword(s):  
Diabetic Nephropathy ◽  
Advanced Glycation End Products ◽  
Bone Disease ◽  
Advanced Glycation ◽  
Adynamic Bone Disease ◽  
Glycation End Products ◽  
End Products ◽  
Adynamic Bone

scholarly journals Advanced Glycation End Products: Building on the Concept of the “Common Soil” in Metabolic Disease

Endocrinology ◽  
2019 ◽  
Vol 161 (1) ◽  
Author(s):  
Henry H Ruiz ◽  
Ravichandran Ramasamy ◽  
Ann Marie Schmidt
Keyword(s):  
Insulin Resistance ◽  
Advanced Glycation End Products ◽  
Metabolic Disorders ◽  
Metabolic Dysfunction ◽  
Advanced Glycation ◽  
Metabolic Dysregulation ◽  
Obesity And Diabetes ◽  
Glycation End Products ◽  
End Products

Abstract The role of advanced glycation end products (AGEs) in promoting and/or exacerbating metabolic dysregulation is being increasingly recognized. AGEs are formed when reducing sugars nonenzymatically bind to proteins or lipids, a process that is enhanced by hyperglycemic and hyperlipidemic environments characteristic of numerous metabolic disorders including obesity, diabetes, and its complications. In this mini-review, we put forth the notion that AGEs span the spectrum from cause to consequence of insulin resistance and diabetes, and represent a “common soil” underlying the pathophysiology of these metabolic disorders. Collectively, the surveyed literature suggests that AGEs, both those that form endogenously as well as exogenous AGEs derived from environmental factors such as pollution, smoking, and “Western”-style diets, contribute to the pathogenesis of obesity and diabetes. Specifically, AGE accumulation in key metabolically relevant organs induces insulin resistance, inflammation, and oxidative stress, which in turn provide substrates for excess AGE formation, thus creating a feed-forward–fueled pathological loop mediating metabolic dysfunction.

Sign in / Sign up

Export Citation Format

Share Document